Prostatic Neoplasms: all 6,484 studies
Page 63 of 65. Open to participants first (1,415), then studies with results posted, then the rest; newest registration first within each.
- GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate CancerCompletedNCT00087165Phase 2
- Docetaxel and Erlotinib in Treating Older Patients With Prostate CancerCompletedNCT00087035Phase 2
- Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical ProstatectomyCompletedNCT00086736Phase 2
- Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the ProstateCompletedNCT00085228Phase 2
- Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008CompletedNCT00084825Phase 2
- Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate CancerWithdrawnNCT00084565Phase 2
- Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate CancerCompletedNCT00084526Phase 1/2
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the ProstateCompletedNCT00083005Phase 2
- Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone PainCompletedNCT00082927Phase 3
- Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate CancerCompletedNCT00082732Phase 1
- Magnetic Resonance Imaging to Locate and Characterize Prostate CancerCompletedNCT00082147Not applicable
- Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With DocetaxelCompletedNCT00082134Phase 2
- Study of CEP-701 in Treatment of Prostate CancerCompletedNCT00081601Phase 2
- Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the ProstateCompletedNCT00081172Phase 2
- Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate CancerCompletedNCT00080808Phase 2
- Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone MetastasesTerminatedNCT00080782Phase 2
- Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone MetastasesCompletedNCT00080678Phase 2
- Study of Motexafin Gadolinium and Docetaxel for Advanced Solid TumorsCompletedNCT00080041Phase 1
- Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the ProstateCompletedNCT00078923Phase 2
- Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate CancerCompletedNCT00078910Phase 2
- Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid TumorsCompletedNCT00078845Phase 2
- PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone TherapyCompletedNCT00078585Phase 2
- Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate CancerCompletedNCT00077402Phase 2
- Clinical Trial for Prostate CancerCompletedNCT00076531Phase 3
- CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate CancerCompletedNCT00075192Phase 1/2
- GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid TumorsCompletedNCT00074022Phase 1/2
- Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical ProstatectomyTerminatedNCT00073970Phase 2
- MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate CancerCompletedNCT00072930Phase 2
- Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)CompletedNCT00072722Phase 2
- A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate CancerCompletedNCT00072670Phase 2
- Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of RelapseCompletedNCT00071968Phase 2
- MLN2704 in Subjects With Metastatic Androgen-Independent Prostate CancerCompletedNCT00070837Phase 1/2
- A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following ProstatectomyCompletedNCT00069888Phase 2
- Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy RegimenCompletedNCT00069745Phase 3
- Lycopene in Treating Patients With Metastatic Prostate CancerCompletedNCT00068731Phase 2
- Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate CancerCompletedNCT00067015Phase 3
- Reiki/Energy Healing in Prostate CancerCompletedNCT00065208Phase 1/2
- Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate CancerCompletedNCT00064610Phase 1/2
- Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate NeoplasiaCompletedNCT00064194Phase 3
- Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1
- The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation TherapyCompletedNCT00063609Phase 4
- Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate CancerCompletedNCT00062309Phase 3
- Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate CancerCompletedNCT00061867Phase 1
- Using Fiducial Markers to Aid in Prostate Cancer Radiation TreatmentCompletedNCT00061347Phase 1
- ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the BodyCompletedNCT00061126Phase 2
- Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate AdenocarcinomaCompletedNCT00061035Phase 1
- Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)CompletedNCT00060476Phase 3
- Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate CancerCompletedNCT00060437Phase 2
- Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate CancerCompletedNCT00060398Phase 3
- Pomegranate Juice in Treating Patients With Recurrent Prostate CancerCompletedNCT00060086Not applicable
- Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate CancerCompletedNCT00059943Phase 2
- Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus MitoxantroneCompletedNCT00059631Phase 1
- Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical ProstatectomyTerminatedNCT00058266Phase 2
- Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00058253Phase 1
- Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate CancerCompletedNCT00058084Phase 2
- Sildenafil in Treating Erectile Dysfunction in Patients With Prostate CancerCompletedNCT00057759Not applicable
- Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate CancerCompletedNCT00056654Not applicable
- Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of RelapseCompletedNCT00055731Phase 3
- Monoclonal Antibody Therapy in Treating Patients With Prostate CancerCompletedNCT00054574Phase 2
- Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation TherapyCompletedNCT00054522Phase 2
- Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate CancerCompletedNCT00054106Phase 1
- 3-AP in Treating Patients With Advanced Prostate CancerCompletedNCT00054015Phase 2
- Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00052845Phase 2
- Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate CancerCompletedNCT00052481
- A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate CancerCompletedNCT00052000Phase 1
- Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory MalignanciesTerminatedNCT00050687Phase 1/2
- Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate CancerCompletedNCT00050596Phase 2
- YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate CancerTerminatedNCT00050297Phase 2
- Low-Fat Diet and/or Flaxseed in Preventing Prostate CancerCompletedNCT00049309Phase 2
- Prevention of Osteoporosis in Men With Prostate CancerCompletedNCT00048841Phase 3
- YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone TherapyTerminatedNCT00048659Phase 2
- Atrasentan in Treating Patients With Prostate CancerCompletedNCT00046943Phase 3
- Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone TherapyCompletedNCT00046826Phase 2
- Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate CancerCompletedNCT00045331Not applicable
- Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate CancerCompletedNCT00045227Phase 2
- R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of RecurrenceStatus unknownNCT00045123Phase 2
- Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate CancerCompletedNCT00044980Not applicable
- ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing TaxotereStatus unknownNCT00043576Phase 2/3
- Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.WithdrawnNCT00043212Phase 3
- Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate CancerCompletedNCT00043069Phase 3
- Isoflavones & Lycopene in Localized Prostate Ca:Prior to Radical ProstatectomyCompletedNCT00042731Not applicable
- Gene-Environment Interaction in Prostate CancerCompletedNCT00041847
- Assessing Quality of Life of Patients With Prostate CancerCompletedNCT00041301
- BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyCompletedNCT00040755Phase 2
- Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2CompletedNCT00040586Phase 2
- Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate CancerTerminatedNCT00040170Phase 2
- Massage Therapy for Cancer-Related FatigueCompletedNCT00039793Phase 2
- Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate CancerCompletedNCT00039624Phase 2
- Biological Therapy in Treating Patients With Prostate CancerCompletedNCT00039299Phase 1
- Zoledronate and BMS-275291 in Treating Patients With Prostate CancerCompletedNCT00039104Phase 2
- Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical FailureCompletedNCT00038662Phase 2
- Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate CarcinomaCompletedNCT00038246Phase 1/2
- Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate CancerCompletedNCT00038194Phase 1
- Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate CancerCompletedNCT00038181Phase 2
- Intravenous Estramustine With Taxol in Hormone Refractory Prostate AdenocarcinomaCompletedNCT00038168Phase 1/2
- Study of Health Promotion in Patients With Early-Stage Breast or Prostate CancerCompletedNCT00037024Not applicable
- Vaccine Therapy Plus QS21 in Treating Patients With Prostate CancerCompletedNCT00036933Phase 1
- Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced CancerCompletedNCT00036790Phase 1
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00036556Phase 3
- A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00036543Phase 3